These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8299363)

  • 21. Prolonged exposure to loteprednol etabonate in human tear fluid and rabbit ocular tissues following topical ocular administration of Lotemax gel, 0.5%.
    Glogowski S; Lowe E; Siou-Mermet R; Ong T; Richardson M
    J Ocul Pharmacol Ther; 2014 Feb; 30(1):66-73. PubMed ID: 24325539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Soft drugs. 18. Oral and rectal delivery of loteprednol etabonate, a novel soft corticosteroid, in rats--for safer treatment of gastrointestinal inflammation.
    Bodor N; Murakami T; Wu WM
    Pharm Res; 1995 Jun; 12(6):869-74. PubMed ID: 7667192
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, characterization and in vitro evaluation of novel shell crosslinked poly(butylene adipate)-co-N-succinyl chitosan nanogels containing loteprednol etabonate: A new system for therapeutic effect enhancement via controlled drug delivery.
    Nasr FH; Khoee S
    Eur J Med Chem; 2015 Sep; 102():132-42. PubMed ID: 26263245
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes.
    Druzgala P; Wu WM; Bodor N
    Curr Eye Res; 1991 Oct; 10(10):933-7. PubMed ID: 1959381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Attenuation of ocular hypertension with the use of topical loteprednol etabonate 0.5% in steroid responders after corneal transplantation.
    Holland EJ; Djalilian AR; Sanderson JP
    Cornea; 2009 Dec; 28(10):1139-43. PubMed ID: 19770719
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adrenal insufficiency and growth failure secondary to inhaled corticosteroids: a paradoxical complication.
    Smith A; Doan ML; Roy D; Pinsker JE
    Clin Pediatr (Phila); 2012 Dec; 51(12):1194-6. PubMed ID: 22387925
    [No Abstract]   [Full Text] [Related]  

  • 27. Fluticasone propionate sensitivity in a patient with contact allergy to multiple corticosteroids.
    Venning VA
    Contact Dermatitis; 1995 Jul; 33(1):48-9. PubMed ID: 7493462
    [No Abstract]   [Full Text] [Related]  

  • 28. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. The Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I.
    Friedlaender MH; Howes J
    Am J Ophthalmol; 1997 Apr; 123(4):455-64. PubMed ID: 9124242
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Loteprednol etabonate: comparison with other steroids in two models of intraocular inflammation.
    Howes JF; Baru H; Vered M; Neumann R
    J Ocul Pharmacol; 1994; 10(1):289-93. PubMed ID: 8207332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhaled corticosteroids and adrenal insufficiency.
    Russell G
    Arch Dis Child; 2002 Dec; 87(6):455-6. PubMed ID: 12456537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemistry of loteprednol etabonate and related steroids. II. Reactions at ring C and NMR structural studies of the resulting compounds.
    Rachwal S; Druzgala P; Liu ZZ; Vlasak J; Brewster ME; Pop E
    Steroids; 1998 Apr; 63(4):193-201. PubMed ID: 9589553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A role for the intranasal formulation of azelastine hydrochloride/fluticasone propionate in the treatment of allergic rhinitis.
    Ridolo E; Montagni M; Melli V; Bonzano L; Incorvaia C; Canonica GW
    Ther Deliv; 2015; 6(6):653-9. PubMed ID: 25913181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent advances in retrometabolic design approaches.
    Bodor N
    J Control Release; 1999 Nov; 62(1-2):209-22. PubMed ID: 10518653
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolism, distribution, and transdermal permeation of a soft corticosteroid, loteprednol etabonate.
    Bodor N; Loftsson T; Wu WM
    Pharm Res; 1992 Oct; 9(10):1275-8. PubMed ID: 1448425
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Isolation and structure elucidation of the major photodegradation products of loteprednol etabonate.
    Shirasaki Y; Inada K; Inoue J; Nakamura M
    Steroids; 2004 Jan; 69(1):23-34. PubMed ID: 14715374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Inhalational corticosteroids in COPD. THe ISOLDE Study (Inhaled Steroids in Obstructive Lung Disease in Europe)].
    Internist (Berl); 2001 Jul; 42(7):1050-2. PubMed ID: 11476049
    [No Abstract]   [Full Text] [Related]  

  • 37. Treatment of seasonal allergic conjunctivitis with ophthalmic corticosteroids: in search of the perfect ocular corticosteroids in the treatment of allergic conjunctivitis.
    Bielory BP; Perez VL; Bielory L
    Curr Opin Allergy Clin Immunol; 2010 Oct; 10(5):469-77. PubMed ID: 20720489
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The position not the presence of the halogen in corticosteroids influences potency and side effects.
    Bikowski J; Pillai R; Shroot B
    J Drugs Dermatol; 2006 Feb; 5(2):125-30. PubMed ID: 16485880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation. Loteprednol Etabonate Post-operative Inflammation Study Group 1.
    Stewart R; Horwitz B; Howes J; Novack GD; Hart K
    J Cataract Refract Surg; 1998 Nov; 24(11):1480-9. PubMed ID: 9818338
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Soft corticosteroids for local immunosuppression: exploring the possibility for the use of loteprednol etabonate for islet transplantation.
    Bocca N; Pileggi A; Molano RD; Marzorati S; Wu W; Bodor N; Ricordi C; Buchwald P
    Pharmazie; 2008 Mar; 63(3):226-32. PubMed ID: 18444512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.